Compare iShares MSCI India ETF (INDA) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI India ETF vs McKesson Corporation — how do they compare? iShares MSCI India ETF trades at $49.96, while McKesson Corporation trades at $901.77 (market cap $105.14B). The key difference: McKesson Corporation pays a 0.42% dividend while iShares MSCI India ETF pays none, and McKesson Corporation is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| INDA | MCK | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $55.29 | $995.69 |
52-Week Low | $45.42 | $659.01 |
Market Cap | — | $105.14B |
Enterprise Value | — | $111.67B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INDA trades at $49.95, down 0.38% on the day, with technical indicators showing a bullish trend supported by moving averages but neutral oscillators. The ETF reflects exposure to India's economy, which grew 7.8% in Q1 2026 (CNBC, 2026-06-05), though financial ratios are unavailable. Recent news highlights sector-specific challenges, including IT weakness and pharmaceutical export hurdles.
The outlook for INDA is mixed, with India's robust economic growth offering long-term potential, but near-term risks from foreign outflows, geopolitical tensions, and sectoral headwinds may pressure performance. Investors should weigh macroeconomic resilience against volatility in key industries like technology and pharma.
McKesson (MCK) trades at $877.87, down 0.23% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company reported robust Q1 2027 results with EPS of $9.93 beating estimates by 20% year-over-year, driven by specialty drug growth and oncology performance. Revenue reached $105.4 billion, up 8%, prompting management to raise full-year adjusted EPS guidance. Analyst consensus remains strongly bullish with 24 buy ratings and a $990.67 price target, representing 13% upside potential.
MCK presents a compelling investment case with consistent earnings beats, raised guidance, and strong operational cash flow of $6.9 billion projected for 2026. Key risks include margin pressure from the low 1.12% net income margin, high accounts payable of $55.33 billion, and negative shareholder equity of -$2.07 billion. The stock's valuation at 24.19 P/E appears reasonable given growth prospects, but investors should monitor debt levels and pharmaceutical pricing dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
